Clinical Research Unit.
The Unitat d’Investigació Clínica (UDIC) was created in 2011 to offer patients an alternative to their unresolved clinical problems, especially in Parkinson’s disease. The beginning is related to the research activity of Dr. Ernest Balaguer at the Hospital Clínic de Barcelona (Neurology service Dr. Eduardo Tolosa) in 1987 with a first trial with subcutaneous Lisuride in fluctuating Parkinson’s disease.
Since the incorporation of Dr. Balaguer in the Hospital General de Catalunya in 1990, he began, together with Dr. Soler Singla, the first trials in acute cerebral vascular pathology. Later, research projects in Parkinson’s disease and in Alzheimer’s disease were expanded. The further development of the UDIC and its professionalization has allowed covering other therapeutic areas: neurodegenerative diseases, epilepsy, multiple sclerosis, fragile X syndrome, restless legs syndrome and progressive supranuclear palsy.
At the same time, projects have been carried out on non-neurological lines such as Hematology, Gynecology, Cardiology and Digestive.
Thus, the UDIC is a multidisciplinary unit with extensive experience in the diagnosis and treatment of neurological and non-neurological diseases, where the care activity and clinical research are perfectly interrelated and integrated. The objective of the UDIC is to contribute to the development of new treatments for diseases with important therapeutic needs, by carrying out clinical trials that follow the standards of Good Clinical Practice, and the applicable legal regulations.
Strict monitoring of the protocols approved by the health authorities is carried out to guarantee the maximum safety of the patients and the best quality of the obtained data.
“ We collaborate with the Neurology service of the Hospital General de Catalunya.”
— Clinical trials are the raison to be of our unit.—
-New antialfasinuclein monoclonal antibody: Innovation in Parkinson’s continues –
-New antipsychotic drug in any type of Dementia-
-“The so-called “vaccines” (passive immunotherapy) are continuing in Alzheimer’s”-
-New antidiscinetic drug in Parkinson-
– A different option in Parkinson: Apomorphine sublingual –
The Unit is formed by expert neurologists in the respective areas, nursing staff, clinical assistants and laboratory technicians, as well as coordinator and data manager, with the support of the entire administrative team. All of them have extensive experience in these activities and have the corresponding accreditations.
We collaborate with professionals in Neuropsychology, Dermatology, Ophthalmology, Cardiology, Digestive and Internal Medicine.
We continuously interact with the central hospital services, such as Clinical Analysis Laboratory, Pharmacy and Diagnostic Imaging (CT, MR, SPECT and TEP).
We have carried out more than 100 clinical trials in Phase I, II and III, in the different areas of related research. All of them are multicenter, international, generally double-blind, placebo-controlled studies, approved by the European Medicines Agency (EMA) and the American Food and Drug Administration (FDA), which have been evaluated and issued by Ethical Committees, according to International standards and guidelines of Good Clinical Practice.
“We have developed these trials at the General University Hospital of Catalonia (Sant Cugat), at the Sant Joan de Déu de Manresa Hospital (Althaia Foundation), at the Sant Andreu de Manresa Hospital (Sant Andreu Salut Foundation) and at the Sant Rafael Hospital from Barcelona (Benito Menni). We also collaborate with Badalona Serveis Assistencials and with the Asil de Granollers Hospital Foundation. The offices … on Tuset 23, 4th floor (Center de Negocis) in Barcelona. “
What do we do?
Our research activity cannot be separated from assistance. We are part of the Neurology Service of the Hospital General de Catalunya that treats patients with diverse neurological problems, both at the level of hospitalization and outpatient follow-up. We have the ability to work together and in a multidisciplinary way with other medical and surgical specialties. Clinical research (clinical trials) Clinical trials are the reason for our unit.
- Investigació clínica (assaigs clínics)
All the medical and organizational complexity surrounding clinical trials forced us to create an entity that had sufficient resources, and was able to support professionals and offer a therapeutic option to patients who are interested in participating in a clinical trial, with the aim of expanding the knowledge of new drugs in different pathologies.
- External consultation:
In the outpatient clinics, patients with diverse pathologies are given services that require a specific diagnosis, treatment and follow-up of their disease. A large majority of patients participating in our unit come from external offices of the HUGC and the other collaborating centers.
Hospitalization: In the area of hospitalization we give support to those patients that require a quick. Also for protocols that require pharmacokinetic studies (phase I trials), periodic clinical assessments or neuroimaging studies
Missió / Visió / Valors
Help people with unresolved medical problems.
To be a leading clinical trials unit in commitment and quality.
-Commitment to people.-, Respect and trust in teamwork. Innovation and constant improvement. Bioethics is our guide.